Kolltan Pharmaceuticals Overview

  • Year Founded
  • 2007

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 46

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $121M

Kolltan Pharmaceuticals General Information

Description

Developer of monoclonal antibody drugs. The company is a clinical-stage enterprise focused on discovery and development of drug candidates targeting receptor tyrosine kinases (RTKs) that impact oncology and immunology. The company's most advanced product candidates include KTN3379, a monoclonal antibody drug candidate targeting ErbB3 (HER3), which is currently in clinical development for the potential treatment of different solid tumors, and KTN0158, a monoclonal antibody targeting KIT, which is in clinical evaluation for cancer and preclinical evaluation for mast cell diseases.

Contact Information

Website
www.kolltan.com
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 300 George Street
  • Suite 530
  • New Haven, CT 06511
  • United States
+1 (203)
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Acquirer
Vertical(s)
Corporate Office
  • 300 George Street
  • Suite 530
  • New Haven, CT 06511
  • United States
+1 (203)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Kolltan Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Merger/Acquisition 29-Nov-2016 $121M Completed Clinical Trials - Phase 1
6. IPO 28-Jan-2015 Cancelled Clinical Trials - Phase 1
5. Later Stage VC (Series D) 17-Mar-2014 Completed Generating Revenue
4. Later Stage VC (Series C) 07-Mar-2012 Completed Startup
3. Early Stage VC (Series B) 20-Jan-2010 Completed Startup
2. Grant 31-Dec-2009 $240K $40M Completed Startup
1. Early Stage VC (Series A) 18-Aug-2009 $40M $40M Completed Startup
To view Kolltan Pharmaceuticals’s complete valuation and funding history, request access »

Kolltan Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series D
Series C
Series B 10,000,000 $0.001000 $0.04 $1.1 $1.1 1x $1.1 6.29%
Series A 40,000,000 $0.001000 $1 $1 1x $1 27.66%
To view Kolltan Pharmaceuticals’s complete cap table history, request access »

Kolltan Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of monoclonal antibody drugs. The company is a clinical-stage enterprise focused on discovery and development
Drug Discovery
New Haven, CT
46 As of 2015

San Rafael, CA
 

Toronto, Canada
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Kolltan Pharmaceuticals Competitors (73)

One of Kolltan Pharmaceuticals’s 73 competitors is BioMarin Pharmaceutical, a Formerly PE-Backed company based in San Rafael, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
BioMarin Pharmaceutical Formerly PE-Backed San Rafael, CA
ProMIS Neurosciences Corporation Toronto, Canada
Camurus Corporation Lund, Sweden
Damora Therapeutics ( Drug Discovery) Formerly VC-backed Waltham, MA
Nexoplex bio Formerly VC-backed Emeryville, CA
You’re viewing 5 of 73 competitors. Get the full list »

Kolltan Pharmaceuticals Patents

Kolltan Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2017035430-A2 Anti-alk antibodies and methods for use thereof Inactive 27-Aug-2015
WO-2017035430-A3 Anti-alk antibodies and methods for use thereof Inactive 27-Aug-2015
WO-2016149265-A1 Anti-met antibodies and methods of use thereof Inactive 16-Mar-2015
WO-2015184231-A2 Regulators of anaplastic lymphoma kinase and uses thereof Inactive 30-May-2014
WO-2015184231-A3 Regulators of anaplastic lymphoma kinase and uses thereof Inactive 30-May-2014 A61K31/727
To view Kolltan Pharmaceuticals’s complete patent history, request access »

Kolltan Pharmaceuticals Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Kolltan Pharmaceuticals Former Investors (18)

Investor Name Investor Type Holding Investor Since Participating Rounds
Auven Therapeutics PE/Buyout Minority
Deerfield Management Venture Capital Minority
Elm Street Ventures VC-Backed Company Minority
Fidelity Corporation Minority
Gilead Corporation Minority
You’re viewing 5 of 18 investors. Get the full list »

Kolltan Pharmaceuticals Acquisitions (1)

Kolltan Pharmaceuticals’s most recent deal was a Merger/Acquisition with Xetrios Therapeutics. The deal was made on 07-Aug-2014.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Xetrios Therapeutics 07-Aug-2014 Merger/Acquisition Other Commercial Services
To view Kolltan Pharmaceuticals’s complete acquisitions history, request access »

Kolltan Pharmaceuticals FAQs

  • When was Kolltan Pharmaceuticals founded?

    Kolltan Pharmaceuticals was founded in 2007.

  • Where is Kolltan Pharmaceuticals headquartered?

    Kolltan Pharmaceuticals is headquartered in New Haven, CT.

  • What is the size of Kolltan Pharmaceuticals?

    Kolltan Pharmaceuticals has 46 total employees.

  • What industry is Kolltan Pharmaceuticals in?

    Kolltan Pharmaceuticals’s primary industry is Drug Discovery.

  • Is Kolltan Pharmaceuticals a private or public company?

    Kolltan Pharmaceuticals is a Private company.

  • What is the current valuation of Kolltan Pharmaceuticals?

    The current valuation of Kolltan Pharmaceuticals is .

  • What is Kolltan Pharmaceuticals’s current revenue?

    The current revenue for Kolltan Pharmaceuticals is .

  • How much funding has Kolltan Pharmaceuticals raised over time?

    Kolltan Pharmaceuticals has raised $140M.

  • Who are Kolltan Pharmaceuticals’s investors?

    Auven Therapeutics, Deerfield Management, Elm Street Ventures, Fidelity, and Gilead are 5 of 18 investors who have invested in Kolltan Pharmaceuticals.

  • Who are Kolltan Pharmaceuticals’s competitors?

    BioMarin Pharmaceutical, ProMIS Neurosciences, Camurus, Damora Therapeutics ( Drug Discovery), and Nexoplex bio are some of the 73 competitors of Kolltan Pharmaceuticals.

  • When was Kolltan Pharmaceuticals acquired?

    Kolltan Pharmaceuticals was acquired on 29-Nov-2016.

  • Who acquired Kolltan Pharmaceuticals?

    Kolltan Pharmaceuticals was acquired by Celldex.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process